The Nobel Prize in Physiology or Medicine for 2011 to Jules Hoffmann, Bruce Beutler, and the late Ralph Steinman recognizes accomplishments in understanding and unifying the two strands of immunology, the evolutionarily ancient innate immune response and modern adaptive immunity.
Among the 15 Nobel prizes given for discoveries in immunology, including the very first, the 2011 prize can be best compared to the 1908 prize, shared by two giants of modern science, Paul Ehrlich and Ilya Metchnikoff. In awarding that prize, the Nobel committee attempted to grapple with the divide that had already arisen in the then infant science of immunology, using the simple award statement, ''in recognition of their work on immunity. '' In fact, Ehrlich (Ehrlich, 1900 ) and Metchnikoff (Metchnikoff, 1891) were the champions of two divergent views of how the body protects itself against foreign invaders. The one concentrated on the exquisitely specific adaptive immune response that exhibited the features of learning and recall and was the basis of the remarkably successful procedure of vaccination, the only medical intervention that has eradicated diseases (two so far, smallpox in humans and rinderpest in cattle). By contrast, the adherents of innate immunity emphasized the near universal capacity of multicellular life forms, including plants, to protect themselves against foreign invaders with extremely effective tools to eliminate or control the invader utilizing the inflammatory system.
We return to this divide in 2011, but not in the stark terms that separated Ehrlich and Metchnikoff. For the work of the new Nobel Laureates-Jules Hoffmann and Bruce Beutler, ''for their discoveries concerning the activation of innate immunity'' and the late Ralph Steinman, ''for his discovery of the dendritic cell and its role in adaptive immunity'' -to a very large degree represents the merging of the two strands and the recognition of the fundamental unity of immune responsiveness. The celebration of immunologists everywhere in response to this well-deserved prize is tempered with sadness, with Ralph Steinman having died on the Friday preceding the Monday announcement of the award.
Exploring Immunology's ''Dirty Little Secret''
The narrative underlying the award to Hoffmann and Beutler, representing innate immunity, and Steinman, very much on the interface between innate and adaptive responses, begins with two independent themes. Although Steinman's key discovery was made earlier, I start with a description of the reawakening of the interest of immunologists in innate immunity. It would be presumptuous to imply that the study of the innate immune system had ceased in the years after Metchnikoff's work. But there can be little doubt that, following the proposal by David Talmage (Talmage, 1957) and by Macfarlane Burnet (Burnet, 1957) of the clonal selection theory of immunity, the attention of the majority of immunologists was riveted on the adaptive system, and most of the other Nobel prizes in immunology (although not all) were for advances in understanding adaptive immunity.
Yet despite this great attention, all was not well in the understanding of how adaptive immune responses were initiated. A great challenge was to determine why the simple introduction of an antigenic protein led to a very weak response or tolerance unless an adjuvant was co-injected to enhance the response. Perhaps the most famous of these was introduced by my predecessor twice removed as chief of the NIAID Laboratory of Immunology, Jules Freund, known for the eponymous complete Freund's adjuvant, consisting of killed Mycobacteria tuberculosis organisms in a water-in-oil emulsion.
Although this need to use adjuvants to obtain a robust immune response to protein antigens was widely appreciated, it was papered over as immunologists' ''dirty little secret.'' In a remarkably prescient and influential lecture at the opening of the 1989 Cold Spring Harbor Symposium on Quantitative Biology (Janeway, 1989) , Charles Janeway motivated immunologists everywhere to think about this problem. Janeway argued that the immune system required not only an antigen/receptor interaction to initiate a response, but a parallel recognition of structures that pathogens expressed (pathogen-associated molecular patterns [PAMPs] ), which would be recognized by receptors broadly expressed by cells of the immune and inflammatory systems (pattern recognition receptors [PRRs] ). He posited that these interactions stimulated cellular events that were essential for the activation, expansion, and differentiation of T and B lymphocytes that would eventually result in elimination or control of the pathogen.
Janeway's proposal of a microbial sensor eliciting an innate immune response that was subsequently interpreted by lymphocytes, the key cells of the adaptive immune system, as ''permission'' to mount a response when they recognized an antigenic substance was enormously influential. Although there was ''no flesh on the bones,'' as I will recount later, the cell that interpreted the innate response to the adaptive system, the dendritic cell, had already been discovered by Ralph Steinman. The key step, the finding of molecular entities that represented the PRRs and the PAMPs, was what truly galvanized the immunological community and led to a revolution in how we understand host-pathogen interactions.
In 1996, Jules Hoffmann, with his colleagues Lemaitre, Nicolas, Michaut, and Reichhart, working at the Institut de Biologie Molé culaire et Cellulaire in Strasbourg, reported that, in Drosophila, an intact gene cassette consisting of spä tzle/Toll/cactus/dorsal was essential if the fly was to mount a potent antifungal response (Lemaitre et al., 1996) . It had already been shown that fly resistance to certain bacterial infections was controlled by the gene designated immune deficiency (imd), but it was clear that many other infections were not controlled by the action of imd alone. Hoffmann and his colleagues became interested in the system that activated the morphogen dorsal because its signaling pathway, initiated by Toll, showed a striking similarity to components of a key activator of vertebrate immune/inflammatory responses, the interleukin 1 (IL-1)/NF-kB signaling pathway. The cytosolic portion of Toll exhibits homology to the comparable region of the IL-1 receptor, and cactus is homologous to a key regulator of NF-kB activation, I-kB, and likewise dorsal to NF-kB. Hoffmann and his colleagues showed that the spä tzle/Toll/ cactus/dorsal signaling pathway controls the production of the antifungal peptide drosomycin and that flies with mutations in this pathway have a dramatic reduction of survival following fungal infection.
This finding was enormously exciting not only for the insight that it gave into how flies (and presumably other invertebrates) protected themselves against key pathogens, but also because its homology to components of the NF-kB system implied that it was likely that humans and other vertebrates might use a related system. However, there was one important point that led to some uncertainty. The activator spä tzle, like human IL-1, was an endogenous extracellular protein, so if this pathway was indeed Janeway's PRR-signaling pathway, how exactly did it sense the pathogen, and how would pathogen sensing occur in vertebrates?
Before describing Beutler's contribution, which gave us insight into the ligands that activated the system in humans, there is an important intermediate finding. Charles Janeway and his then postdoctoral fellow Ruslan Medzhitov, working at Yale University, immediately recognized that the finding by Hoffmann in flies provided a powerful tool that might aid in determining the nature of microbial sensors in humans. Medzhitov and Janeway scanned the expressed sequence tag database and found a transcript that encoded a homolog of Drosophila Toll. They wished to determine whether this human Toll homolog initiated activation of NF-kB, as Drosophila Toll did, and led to the release of key proinflammatory cytokines. Because Medzhitov and Janeway did not know the ligand for their ''Toll-like receptor'' (TLR), they prepared a molecular chimera in which the extracellular domain of the T cell differentiation marker CD4 was linked to the cytosolic domain of the TLR that they had identified. They expressed this chimera in a human monocyte cell line and showed that, when crosslinked with an anti-CD4 antibody, NF-kB was activated and a series of proinflammatory cytokines were produced, including IL-1, IL-6, and IL-8. This work, published in 1997 (Medzhitov et al., 1997) , established that humans had at least one Toll homolog (this proved to be TLR4) and that its signaling properties resembled those of Drosophila Toll and of human IL-1. This still left unknown what TLRs recognized and thus whether the TLRs were the microbial sensors/PRRs that Janeway had postulated. Tragically, Janeway died in 2003. By way of disclosure, I had the good fortune to be his postdoctoral mentor.
The illumination of TLR recognition specificity came from the efforts of Bruce Beutler. Beutler had been a postdoctoral fellow at the Rockefeller University working with Anthony Cerami, where they codiscovered the proinflammatory cytokine TNFa (Beutler et al., 1985) . He then joined the faculty of the University of Texas Southwestern Medical Center in Dallas, where he set himself the task of determining the genetic defect that rendered some mice unresponsive to lipopolysaccharide (LPS), a bacterial endotoxin. He took advantage of the existence of two sets of closely related strains of mice, C3H/HeJ/C3H/HeN and C57BL/10ScCr/ C57BL/10ScSn, one of which could respond to LPS and one that failed to respond. To type these mice, he made use of the capacity of macrophages from wild-type mice to produce TNFa upon stimulation with LPS and the failure of macrophages from mutant mice to do so. Using a positional cloning effort over a period of several years, he reported in 1998 (Poltorak et al., 1998 ) that the gene that was mutant in the LPS unresponsive mice was Tlr4, which coded for the very TLR that Medzhitov and Janeway had shown could activate NF-kB and cause proinflammatory cytokine production when crosslinked. This indicated that LPS was a direct or indirect ligand for TLR4 and showed that precisely the type of molecule that would fit into Janeway's postulated set of PAMPs could activate production of potent mediators of inflammation.
Of course, as is true of all seminal discoveries, what I have described is merely the thin edge of the wedge. The study of the TLRs as microbial sensors has truly burgeoned, enlisting a legion of extremely gifted investigators who have identified ligands for each of the TLRs. Of these, Shizuo Akira of Osaka University is the generally acknowledged leader, combining gene knockout technology and elegant biochemistry to determine which of the microbial products activate which TLRs. The ligands include doublestranded RNA, single-stranded RNA, CpG oligodeoxynucleotides, bacterial flagellin, lipopeptides, and zymosan, a list that is precisely one that Janeway would have constructed as among his PAMPs. These scientists have worked out TLR subcellular localization (some are in endocytic vesicles, others on the cell surface) and have determined in detail the signaling mechanisms and the products of these signaling pathways. Indeed, shortly after Beutler's publication that TLR4 controlled LPS responses, Akira and his colleagues reported that deleting Myd88, a key signaling intermediate in the IL-1 pathway, blocked much of the action of LPS (Kawai et al., 1999) .
Equally important has been the recognition that the TLRs are but one system of microbial sensors. Other PRRs existsome that have been long-known and others, particularly those found in the cytosol, that have been recently identified.
In some cases, a recognition element is linked through an intermediate to an effector, often by assembly into a molecular complex, an inflammasome. Often, the key effector event is the activation of caspase 1 so that it can cleave its targets, one of the most important being pro-IL-1b, giving rise to biologically active IL-1b.
The Unification of Innate and Adaptive Immunity
The adaptive system consists of two broad sets of antigen-responsive cells, the B and T lymphocytes. B lymphocytes are the precursors of antibody-producing cells, and they use antibody in a membrane protein from as their antigenbinding receptors. Antibodies are capable of recognizing three-dimensional structures and thus can interact with and lead to the neutralization of pathogens in extracellular fluid. B cell receptors recognize the same structures, and though it now appears that this recognition often occurs on cell surfaces, soluble molecules can certainly bind to B cell receptors and, when in a multivalent conformation, can elicit stimulatory signals in the B cell.
By contrast, the T cell antigen recognition system is not adapted to the recognition of three-dimensional structures on the surface of pathogens. Rather, T cell receptors recognize a complex consisting of an antigen-derived peptide bound into a specialized groove in class I and class II major histocompatibility complex (MHC) molecules. As such, T cell recognition of antigen occurs on the surface of cells expressing these peptide/MHC complexes, often referred to as antigen-presenting cells (APCs). In the late 1960s and early 1970s, when the requirement for APCs was first appreciated, it was generally believed that macrophages and possibly B cells were the major APCs. In 1973, Ralph Steinman and his mentor at the Rockefeller University, Zanvil Cohn (who died in 1993), identified a rare cell in spleen and lymph nodes of mice (Steinman and Cohn, 1973) . These cells had a stellate morphology; Steinman and Cohn designated them dendritic cells. In 1974, they published evidence that these cells had potent immunostimulatory activity (Steinman and Cohn, 1974) . This report was initially received with some skepticism, based on the widely held view that the major APCs were the far more numerous macrophages and on the uncertainty that many immunologists had about the assay that Steinman and Cohn used to establish the function of their dendritic cells.
One major function mediated by T cells is the response to the major histocompatibility antigens expressed by animals of distinct MHC type. The in vitro assay that was used to measure this was the ''mixed lymphocyte response'' (MLR) in which T cells from mice of one MHC type would proliferate vigorously when stimulated by APCs from mice of another MHC type. Given that the nature of the actual entity recognized in the MLR was not clear and no T cell priming was required to obtain a vigorous response, many immunologists who studied T cell responses to conventional antigens and measured in vitro T cell proliferation when primed cells were challenged with antigen were uncertain as to the proper interpretation of the MLR data. However, this uncertainty was resolved in a series of experiments, beginning with a key study done by Michel Nussenzweig (then a Ph.D. student) with Steinman and Cohn (Nussenzweig et al., 1980) , in which it was shown that dendritic cells were the key APCs for the development of antigen-specific cytotoxic T cells. This series of studies demonstrated the critical role of dendritic cells in nearly all aspects of T cell activation and established that their potency as APCs far exceeded that of other cell types that expressed MHC molecules, most particularly of macrophages and B cells. Indeed, modern techniques that led to the deletion of dendritic cells result in a profound inability to mount adaptive immune responses.
Dendritic cells consist of many subtypes, but the principles underlying their function, largely established by Steinman and his colleagues, are quite similar. They are found in nearly every organ and initially exist in a state in which they are adapted to the capture of antigen and to the receipt of activating signals. An illustrative example is a population of skin cells known as epidermal Langerhans cells. These skin cells express cell surface molecules that aid in the capture of antigen. They include Fc receptors, which are effective in binding of antigenantibody complexes, receptors for complement, mannose receptors and lectins, and receptors for dying cells, among many others. They also express TLRs. Thus, as sentinels in the tissues, Langerhans cells (and other tissue dendritic cells) can capture antigen from pathogenic microbes or from other cells infected by those organisms. They possess the microbial sensors that determine how they should behave. If appropriately stimulated (for example, by LPS acting on TLR4), they change their phenotype from cells specialized for antigen capture to cells adapted for antigen presentation, and they migrate from the tissue into the draining lymph node. These stimulated dendritic cells acquire enhanced capacity to process and present antigen, including the striking upregulation of class II MHC molecules; they increase their expression of potent costimulatory molecules such as CD80 and CD86 as well as Notch ligands that allow them to efficiently activate those CD4 or CD8 T cells that have recognized antigen on their surface, and they secrete cytokines important in the differentiation of the activated T cells, such as IL-6, IL-12, and IL-23. Indeed, the pattern of cytokines that the dendritic cells produce and their efficiency in processing antigen to a large extent determine the phenotype that the differentiating T cells will adopt. Among CD4 T cells, this would be whether they develop into Th1, Th2, Th17, or induced T regulatory cells and thus regulate immune responses adapted to control distinct types of infections.
Steinman and Nussenzweig also pioneered the idea that a population of dendritic cells resident in lymphoid tissues continuously capture self-antigens and present these antigens to circulating T cells that are specific for them in interactions that, rather than activating the cells, lead either to their elimination or to their development into regulatory T cells (Tregs), effectively enforcing peripheral immunologic tolerance (Hawiger et al., 2001) .
One of Steinman's visions was the use of dendritic cells to develop a new generation of vaccines in which antigens were loaded into dendritic cells in vitro and reinjected or vaccine antigens would be targeted to them and efficiently loaded in vivo. Major efforts at developing dendritic cell-based vaccines are underway (Steinman, 2008) . Indeed, during his long bout with pancreatic cancer, Steinman was treated with a dendritic cell vaccine prepared with antigens derived from his tumor cells.
